{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02079324",
      "OrgStudyIdInfo": {
        "OrgStudyId": "GX-051_HNC_1"
      },
      "Organization": {
        "OrgFullName": "Genexine, Inc.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer",
      "OfficialTitle": "A Single Center, Open-Label, Accelerated Titration, Dose-Escalating, Phase Ι Study to Evaluate the Safety and Tolerability of IT Injection GX-051, Stem Cell Based Gene Therapeutics in Patients With Very Advanced Head and Neck Cancer",
      "Acronym": "GX-051"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2014",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 2016",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 2016",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 27, 2014",
      "StudyFirstSubmitQCDate": "March 4, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 5, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "April 29, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 30, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Genexine, Inc.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this research is to evaluate MTD, Safety and efficacy of GX-051 after intratumoral injection in head and neck cancer patience.",
      "DetailedDescription": "The primary purpose of the study is to determine MTD(Maximum Tolerable Dose) of GX-051 administered in tumor. The second purpose is to evaluate safety and efficacy of GX-051."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Head and Neck Cancer"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "head and neck cancer",
          "gene therapy",
          "stem cell therapy",
          "immunotherappy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "12",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "GX-051",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "GX-051 intratumoral injection",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: GX-051"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "GX-051",
            "InterventionDescription": "intratumoral injection",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "GX-051"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "MTD after GX-051 intratumoral injection",
            "PrimaryOutcomeTimeFrame": "2 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Adverse events after GX-051 intratumoral injection",
            "SecondaryOutcomeTimeFrame": "2 months"
          },
          {
            "SecondaryOutcomeMeasure": "Anti-tumor response by RECIST 1.1 on computed tomography",
            "SecondaryOutcomeDescription": "Response Evaluation Criteria in Solid Tumors (RECIST) are used to determine objective clinical response. Complete Rresponse (CR) is the disappearance of all target lesions, partial response (PR) is at least a 30% decrease in the target lesions, progressive disease (PD) is at least a 20% increase in the target lesions or appearance of one or more new lesions, and stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.",
            "SecondaryOutcomeTimeFrame": "2 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes of INF-γ and IL-12 levels in blood comparing to the baseline after GX-051 intratumoral injection",
            "SecondaryOutcomeDescription": "unit: pg/ml",
            "SecondaryOutcomeTimeFrame": "2 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes of immune cell distribution in tumor tissue after GX-051 intratumoral injection",
            "SecondaryOutcomeDescription": "We will analyze immune cells such as CD4+ T cell, CD8+ T cell, NK cell by FACS analysis on day 1(baseline), day 29(end of treatment) and day 57(follow up)",
            "SecondaryOutcomeTimeFrame": "2 months"
          },
          {
            "SecondaryOutcomeMeasure": "Evaluation of antibody generation against IL-12 which is active ingredient of GX-051",
            "SecondaryOutcomeDescription": "We will analyze anti-IL-12 antibody in blood by ELISA on the screening visit and the follw up visit. Result will report as existence or absence of the anti-body .",
            "SecondaryOutcomeTimeFrame": "2 months"
          },
          {
            "SecondaryOutcomeMeasure": "Evaluation of long term safety examined by vital sign, physical examination, clinical laboratory tests, CT etc",
            "SecondaryOutcomeDescription": "Safety profile would be examined by vital sign, physical examination, clinical laboratory tests, CT etc",
            "SecondaryOutcomeTimeFrame": "17 monthes"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAre capable of understanding and complying with the requirements of the study and have signed the informed consent from (ICF).\nVery advanced head and neck cancer aged more than 19.\nLongest distance of the tumor is bigger than 1 cm and capable of Intratumoral injection.\nBaseline ECOG Performance Status 0, 1 or 2.\nHave a life expectancy more than 6 months.\n\nExclusion Criteria:\n\nHave no history of prior anticancer treatment.\nFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.Subject who have participated in a clinical trial of an treatment vaccine or immunotherapy in an year.\nHave a tumor which is near a main vessel that can be occured embolism after injection or which has hypervascularity.\nPatients currently receiving anticancer immuno-therapies Patients who have received prior treatment with an stem cell therapy.\nHave autoimmune disease (multiple sclerosis, systemic lupus erythromatosis, thyroiditis, psoriasis, inflammatory bowel diseases etc.).\nHave Graft rejection reaction such as GVHD.\nHave immunodeficiency disease.\nLeukocytes< 3.0 x109/L.\nAbsolute neutrophil count < 1.5x109/L.\nPlatelet count < 100 x 109/L.\nHave known positive test for hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV).\nAlanine Aminotransferase (ALT) > 2.5xUNL.\nAspartate Aminotransferase (AST)> 2.5xUNL.\nTotal Bilirubin> UNL.\nHave blood Creatinine> UNL.\nKnown allergy to IL-12 or the excipient(s) of the study medication including fetal bovine serum.\nSecond primary cancer Metastatic brain tumor or meningioma.\nHave a tumor near a main artery.\nUncontrolled hypertension.\nUncontrolled diabetes uncontrolled (arrhythmia).\nHeart failure (more than NYHA Functional Class II); unstable coronary artery disease; myocardial infarction within 6 months.\nChild-Pugh Class C hepatic impairment.\nSevere renal impairment (creatinine clearance < 30 ml/min) or on dialysis.\nHave active infection or history of recurrent infection.\nPatients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.\nAre considered ineligible by the investigator due to a mental disease or CNS disease.\nAdministration of any other tumor therapy, including chemotherapy and radiotherapy within 4 weeks(6 weeks in case of nitrosoureas and mytomycin C) before the beginning of study treatment.\nPatients receiving chronic, systemic treatment with immunosuppressive agent(steroid) or immuno-modulator within 2 weeks prior to screening.\nHave participated in another clinical trial within 30 days prior to dosing.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "19 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Minsik Kim, M.D.",
            "OverallOfficialAffiliation": "Seoul St.Mary's Hospital of the Catholic University of Korea",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Hyun-Tak Jin, ph.D.",
            "OverallOfficialAffiliation": "Genexine, Inc.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Seoul St.Mary's Hospital of the Catholic University of Korea",
            "LocationCity": "Seoul",
            "LocationZip": "137-701",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006258",
            "ConditionMeshTerm": "Head and Neck Neoplasms"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8500",
            "ConditionBrowseLeafName": "Head and Neck Neoplasms",
            "ConditionBrowseLeafAsFound": "Head and Neck Cancer",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M5415",
            "InterventionBrowseLeafName": "Coal Tar",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}